Literature DB >> 14701845

Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4.

Qiang Zhao1, Frank Boschelli, Avrom J Caplan, Kim T Arndt.   

Abstract

Cdc37 is a molecular chaperone that is important for the stability and activity of several protein kinases, including Cdk4 and Raf1. We first determined, using in vitro assays, that Cdc37 binds to the amino-terminal lobe of Cdk4. Subsequent mutagenesis revealed that Gly-15 (G15A) and Gly-18 (G18A) were critical for Cdc37-Cdk4 complex formation. Gly-15 and Gly-18 of Cdk4 are within the conserved Gly-X-Gly-X-X-Gly motif that is required for ATP binding to the kinase. Mutation of either glycine at the equivalent positions of Raf1 (G358A and G361A) also inhibited Cdc37 binding to Raf1. Replacing another conserved residue critical for ATP binding and kinase activity, Lys-35 (K35A), reduced Cdc37-Cdk4 complex formation but to a lesser extent. The interaction of Cdk4 with Cdc37 in vitro was not sensitive to changes in ATP levels. Cell-based assays indicated that Cdk4(G15A) and Cdk4(G18A) were present at the same level as wild type Cdk4. Equivalent amounts of p16 bound to Cdk4(G15A) and Cdk4(G18A) relative to wild type Cdk4, suggesting that Cdk4(G15A) and Cdk4(G18A) adopt significant tertiary structure. However, in contrast to wild type Cdk4, Cdk4(G15A), and Cdk4(G18A) had greatly reduced binding of cyclin D1, Cdc37, and Hsp90. Importantly, overexpression of Cdc37 not only stimulated cyclin D1 binding to wild type Cdk4 but also restored its binding to Cdk4(G15A). Under the same conditions, p16 binding to wild type Cdk4 was suppressed. Our findings show that the interaction of Cdc37 with its client protein kinases requires amino acid residues within a motif that is present in many protein kinases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14701845     DOI: 10.1074/jbc.M308242200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  25 in total

1.  Structure of an Hsp90-Cdc37-Cdk4 complex.

Authors:  Cara K Vaughan; Ulrich Gohlke; Frank Sobott; Valerie M Good; Maruf M U Ali; Chrisostomos Prodromou; Carol V Robinson; Helen R Saibil; Laurence H Pearl
Journal:  Mol Cell       Date:  2006-09-01       Impact factor: 17.970

2.  Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases.

Authors:  Kazuya Terasawa; Katsuhiko Yoshimatsu; Shun-Ichiro Iemura; Tohru Natsume; Keiji Tanaka; Yasufumi Minami
Journal:  Mol Cell Biol       Date:  2006-05       Impact factor: 4.272

3.  Crystal structure of human CDK4 in complex with a D-type cyclin.

Authors:  Philip J Day; Anne Cleasby; Ian J Tickle; Marc O'Reilly; Joe E Coyle; Finn P Holding; Rachel L McMenamin; Jeff Yon; Rajiv Chopra; Christoph Lengauer; Harren Jhoti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-23       Impact factor: 11.205

Review 4.  Functions of the Hsp90 chaperone system: lifting client proteins to new heights.

Authors:  Julia M Eckl; Klaus Richter
Journal:  Int J Biochem Mol Biol       Date:  2013-12-15

5.  Molecular Mechanism of Protein Kinase Recognition and Sorting by the Hsp90 Kinome-Specific Cochaperone Cdc37.

Authors:  Dimitra Keramisanou; Adam Aboalroub; Ziming Zhang; Wenjun Liu; Devon Marshall; Andrea Diviney; Randy W Larsen; Ralf Landgraf; Ioannis Gelis
Journal:  Mol Cell       Date:  2016-04-21       Impact factor: 17.970

6.  CDC25A targeting by miR-483-3p decreases CCND-CDK4/6 assembly and contributes to cell cycle arrest.

Authors:  T Bertero; C Gastaldi; I Bourget-Ponzio; B Mari; G Meneguzzi; P Barbry; G Ponzio; R Rezzonico
Journal:  Cell Death Differ       Date:  2013-02-22       Impact factor: 15.828

7.  Hsp90·Cdc37 Complexes with Protein Kinases Form Cooperatively with Multiple Distinct Interaction Sites.

Authors:  Julia M Eckl; Matthias J Scherr; Lee Freiburger; Marina A Daake; Michael Sattler; Klaus Richter
Journal:  J Biol Chem       Date:  2015-10-28       Impact factor: 5.157

8.  p53 regulates Hsp90beta during arsenite-induced cytotoxicity in glutathione-deficient cells.

Authors:  Geetha M Habib
Journal:  Arch Biochem Biophys       Date:  2008-10-26       Impact factor: 4.013

Review 9.  An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.

Authors:  Marie Robert; Jean-Sébastien Frenel; Emmanuelle Bourbouloux; Dominique Berton Rigaud; Anne Patsouris; Paule Augereau; Carole Gourmelon; Mario Campone
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

10.  Ydj1 protects nascent protein kinases from degradation and controls the rate of their maturation.

Authors:  Atin K Mandal; Nadinath B Nillegoda; Jennifer A Chen; Avrom J Caplan
Journal:  Mol Cell Biol       Date:  2008-04-28       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.